Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 2, 2007, Pages 157-164

  Wang, Shan ^a   Jiang, Jun Lin ^a   Hu, Chang Ping ^a   Zhang, Xiao Jie ^a   Yang, Dong Liang ^a   Li, Yuan Jian ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Asymmetric dimethylarginine (ADMA); Diabetes mellitus; Intercellular adhesion molecule (ICAM 1); Nuclear factor B (NF B); Rosiglitazone; Tumour necrosis factor (TNF )

Indexed keywords

ACETYLCHOLINE; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LIPID; LOW DENSITY LIPOPROTEIN; N(G),N(G) DIMETHYLARGININE; NITRATE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; ROSIGLITAZONE; STREPTOZOCIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERY DILATATION; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CAROTID ARTERY; CELL CULTURE; CHOLESTEROL BLOOD LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENDOTHELIUM LESION; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INFLAMMATION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR RING;

ACETYLCHOLINE; ANIMALS; AORTA; ARGININE; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; ENDOTHELIUM, VASCULAR; HYPOGLYCEMIC AGENTS; INTERCELLULAR ADHESION MOLECULE-1; MALE; MUSCLE, SMOOTH, VASCULAR; NITRATES; NITRIC OXIDE SYNTHASE; NITRITES; RATS; RATS, SPRAGUE-DAWLEY; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA; VASODILATION;

EID: 33847229152     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.662     Document Type: Article

References (30)

1. Rodriguez-Manas L, Angulo J, Peiro C, et al. Endothelial dysfunction and metabolic control in streptozotocin-induced diabetic rats. Br J Pharmacol 1998; 123: 1495-1502.
2. Vehkavaara S, Makimattila S, Schlenzka A, et al. Insulin therapy improves endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2000; 20: 545-550.
3. Xiong Y, Fu YF, Fu SH, et al. Elevated levels of the serum endogenous inhibitor of nitric oxide synthase and metabolic control in rats with streptozotocin-induced diabetes. J Cardiovasc Phannacol 2003; 42: 191-196.
4. Boger RH, Bode-Boger SM, Tsao PS, et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000; 36: 2287-2295.
5. Goonasekera CD, Shah V, Rees DD, et al. Vascular endothelial cell activation associated with increased plasma asymmetric dimethyl arginine in children and young adults with hypertension: a basis for atheroma? Blood Press 2000; 9: 16-21.
6. Zoccali C, Zoccali C, Benedetto FA, et al. Asymmetric dimethylarginine, C-reactive protein and carotid intima-media thickness in end-stage renal disease. J Am Soc Nephrol 2002; 13: 490-496.
7. Pistrosch F, Passauer J, Fischer S, et al. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 2004; 27: 484-490.
8. Stuhlinger MC, Abbasi F, Chu JW, et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
9. Blanquart C, Barbier O, Fruchart JC, et al. Peroxisome proliferator-activated receptors: regulation of transcriptional activities and roles in inflammation. J Steroid Biochem Mol Biol 2003; 85: 267-273.
10. Pasceri V, Wu HD, Willerson JT, et al. Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 2000; 101: 235-238.
11. Diep QN, El Mabrouk M, Cohn JS, et al. Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296-2302.
12. Feng Q, Lu X, Jones DL, et al. Increased inducible nitric oxide synthase expression contributes to myocardial dysfunction and higher mortality after myocardial infarction in mice. Circulation 2001; 104: 700-704.
13. Jiang JL, Li NS, Li YJ, et al. Probucol preserves endothelial function by reduction of the endogenous nitric oxide synthase inhibitor level. Br J Pharmacol 2002; 135: 1175-1182.
14. Kiemer AK, Vollmar AM. Autocrine regulation of inducible nitricoxide synthase in macrophages by atrial natriuretic peptide. J Biol Chem 1998; 273: 13444-13451.
15. Ignarro LJ, Buga GM, Wei LH, et al. Role of the arginine-nitric oxide pathway in the regulation of vascular smooth muscle cell proliferation. Proc Natl Acad Sci U S A 2001; 98: 4202-4208.
16. Kelly RA, Balligand JL, Smith TW. Nitric oxide and cardiac function. Circ Res 1996; 79: 363-380.
17. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992; 339: 572-575.
18. Kurose I, Wolf R, Grisham MB, et al. Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules. Am J Physiol 1995; 268: H2224-H2231.
19. Masuda H, Goto M, Tamaoki S, et al. Accelerated intimal hyperplasia and increased endogenous inhibitors for NO synthesis in rabbits with alloxan-induced hyperglycaemia. Br J Pharmacol 1999; 126: 211-218.
20. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine dimethylammohydrolase pathway. Arterioscler Thromb Vasc Biol 2004; 24: 1023-1030.
21. Hernandez R, Teruel T, Lorenzo M. Rosiglitazone produces insulin sensitisation by increasing expression of the insulin receptor and its tyrosine kinase activity in brown adipocytes. Diabetologia 2003; 46: 1618-1628.
22. Korolkiewicz R, Rekowski P, Szyk A, et al. Effects of diabetes mellitus on the contractile activity of carbachol and galanin in isolated gastric fundus strips of rats. Pharmacology 1998; 57: 65-78.
23. Zhou XJ, Shen JX, Huang L. Study of the mechanism of preventing proteinuria by Yishen Gujing Decoction (YSGJD) in early diabetic-nephropathy. Zhong Xi Yi Jie He Xue Bao 2003; 1: 39-41.
24. Abdel Aziz MT, Fouad HH, Mohsen GA, et al. TNF-alpha and homocysteine levels in type 1 diabetes mellitus. East Mediterr Health J 2001; 7: 679-688.
25. Foss MC, Foss NT, Paccola GM, et al. Serum levels of tumor necrosis factor in insulin-dependent diabetic patients. Braz J Med Biol Res 1992; 25: 239-242.
26. Elhadd TA, Kennedy G, Robb R, et al. Elevated soluble cell adhesion molecules E-selectin and intercellular cell adhesion molecule-1 in type-2 diabetic patients with and without asymptomatic peripheral arterial disease. Int Angiol 2004; 23: 128-133.
27. Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elderly: the cardiovascular health study. Diabetes 2001; 50: 2384-2389.
28. Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001; 286: 327-334.
29. Mohanty P, Aljada A, Ghanim H, et al. Evidence for a potent antiinflammatory effect of rosiglitazone. Clin Endocrinol Metab 2004; 89: 2728-2735.
30. Haffner SM, Greenberg AS, Weston WM, et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.